Erratum: Secondary prevention for patients after a myocardial infarction: Summary of updated NICE guidance ((BMJ (2013) 347 (f6544) DOI: 10.1136/bmj.f6544);Secondary prevention for patients after a myocardial infarction: Summary of updated NICE guidance

BMJ (Online)

Volumn 347, Issue , 2013, Pages

  Jones, Katie ^a   Saxon, Leanne ^a   Cunningham, William ^b   Adams, Phil ^c  

^a ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^b Hadrian Primary Care Alliance   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; TICAGRELOR;

ACUTE CORONARY SYNDROME; ALCOHOL CONSUMPTION; DRUG DOSE TITRATION; FAT INTAKE; FEEDING BEHAVIOR; HEART INFARCTION; HEART REHABILITATION; HOSPITAL DISCHARGE; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEDITERRANEAN DIET; PATIENT CARE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SECONDARY PREVENTION; SHORT SURVEY; SMOKING CESSATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT PLANNING; WEIGHT CONTROL; ARTICLE; RECURRENT DISEASE; RISK REDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RISK REDUCTION BEHAVIOR;

EID: 84888245059     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.m4947     Document Type: Erratum

References (14)

1. National Institute for Health and Care Excellence. Secondary prevention in primary and secondary care for patients following a myocardial infarction. (Clinical guideline 48.) 2007. www.nice.org.uk/CG48.
2. National Institute for Health and Care Excellence. Secondary prevention in primary and secondary care for patients following a myocardial infarction. (Clinical guideline 172.) 2013. www.nice.org.uk/CG172.
3. National Institute for Health and Care Excellence. Brief interventions and referral for smoking cessation in primary care and other settings. (Public health guidance 1.) 2006. www.nice.org.uk/PH1.
4. National Institute for Health and Care Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. (Clinical guideline 43.) 2006. www.nice.org.uk/CG43.
5. British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary . BMA, RPS, 2013. (No 66.)
6. National Institute for Health and Care Excellence. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention. (Technology appraisal 182.) 2009. www.nice.org.uk/TA182.
7. National Institute for Health and Care Excellence. Myocardial infarction with ST-segment elevation: the acute management of myocardial infarction with ST-segment elevation. (Clinical guideline 167.) 2013. www.nice.org.uk/CG167.
8. National Institute for Health and Care Excellence. Unstable angina and NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction. (Clinical guideline 94.) 2010. www.nice.org.uk/CG94.
9. National Institute for Health and Care Excellence. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. (Clinical guideline 67.) 2008. www.nice.org.uk/CG67.
10. National Institute for Health and Care Excellence. Dyspepsia: Managing dyspepsia in adults in primary care. (Clinical guideline 17.) 2004. www.nice.org.uk/CG17.
11. National Institute for Health and Care Excellence. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome. (Technology appraisal 80.) 2004. www.nice.org.uk/TA80.
12. National Institute for Health and Care Excellence. Ticagrelor for the treatment of acute coronary syndromes (ACS). (Technology appraisal 236.) 2011. www.nice.org.uk/TA236.
13. National Insitute for Health and Care Excellence. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal guidance 90). (Technology appraisal 210.) 2010. www.nice.org.uk/TA210.
14. National Institute for Health and Care Excellence. Quality and Outcomes Framework: NICE menu of indicators. www.nice.org.uk/aboutnice/qof/indicators. jsp.